Stock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth

Stock Track11-07

Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking optimism in the market.

Iovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.

The strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, including positive interim data from the IOV-LUN-202 clinical trial for lifileucel in non-small cell lung cancer (NSCLC). The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million, further boosting investor confidence in its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164731139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164731139","market":"us","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking optimism in the market.</p>\n\n<p>Iovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.</p>\n\n<p>The strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, including positive interim data from the IOV-LUN-202 clinical trial for lifileucel in non-small cell lung cancer (NSCLC). The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million, further boosting investor confidence in its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking optimism in the market.</p>\n\n<p>Iovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.</p>\n\n<p>The strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, including positive interim data from the IOV-LUN-202 clinical trial for lifileucel in non-small cell lung cancer (NSCLC). The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million, further boosting investor confidence in its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1164731139","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164731139","pubTimestamp":1762477401,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Iovance Biotherapeutics飙升6.93%，得益于强劲的Q3业绩和营收增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking optimism in the market.\nIovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.\nThe strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, including positive interim data from the IOV-LUN-202 clinical trial for lifileucel in non-small cell lung cancer (NSCLC). The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million, further boosting investor confidence in its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164731139","isCrawlerRequest":true}